{"Title":"Akcea Therapeutics","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"30","Founded":"","Address":"","Phone":"(617) 207-0202","Web_address":"http://www.akceatx.com","Market_cup":"$513.6mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-127.6 mil (last 12 months)","Symbol":"AKCA","Exchange":"NASDAQ","Shares":"15.6","Price_range":"$8.00 - $8.00","Est_volume":"$125.0 mil","Manager":"Cowen and Company/ Stifel/ Wells Fargo Securities","CO_managers":"BMO Capital Markets","Exp_to_trade":"7/14/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. Our goal is to become the premier company offering treatments for inadequately treated lipid disorders. We are advancing a mature pipeline of four novel drugs with the potential to treat multiple diseases. Our drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by IonisÂ Pharmaceuticals, Inc., or Ionis."}